CA2968995A1 - Anti-ganglioside compound for targeting cancer and generating antibodies - Google Patents

Anti-ganglioside compound for targeting cancer and generating antibodies Download PDF

Info

Publication number
CA2968995A1
CA2968995A1 CA2968995A CA2968995A CA2968995A1 CA 2968995 A1 CA2968995 A1 CA 2968995A1 CA 2968995 A CA2968995 A CA 2968995A CA 2968995 A CA2968995 A CA 2968995A CA 2968995 A1 CA2968995 A1 CA 2968995A1
Authority
CA
Canada
Prior art keywords
carbohydrate
ganglioside
cancer
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2968995A
Other languages
English (en)
French (fr)
Inventor
Uri H. Saragovi
Wenyong TONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Institution for the Advancement of Learning
Original Assignee
Royal Institution for the Advancement of Learning
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Institution for the Advancement of Learning filed Critical Royal Institution for the Advancement of Learning
Publication of CA2968995A1 publication Critical patent/CA2968995A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2968995A 2013-12-06 2014-12-04 Anti-ganglioside compound for targeting cancer and generating antibodies Abandoned CA2968995A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912684P 2013-12-06 2013-12-06
US61/912,684 2013-12-06
PCT/CA2014/051165 WO2015081438A1 (en) 2013-12-06 2014-12-04 Anti-ganglioside compound for targeting cancer and generating antibodies

Publications (1)

Publication Number Publication Date
CA2968995A1 true CA2968995A1 (en) 2015-06-11

Family

ID=53272688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2968995A Abandoned CA2968995A1 (en) 2013-12-06 2014-12-04 Anti-ganglioside compound for targeting cancer and generating antibodies

Country Status (7)

Country Link
US (1) US10363305B2 (https=)
EP (2) EP3957327A1 (https=)
JP (1) JP2016539172A (https=)
CN (1) CN106414472A (https=)
CA (1) CA2968995A1 (https=)
ES (1) ES2904533T3 (https=)
WO (1) WO2015081438A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112669A1 (en) * 2016-12-23 2018-06-28 Realist Pharma, Inc. Ganglioside carbohydrate structures and uses thereof
WO2022076364A1 (en) * 2020-10-05 2022-04-14 Aoa Dx Compositions and methods for cancer diagnosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372783T1 (de) * 1993-01-22 2007-09-15 Sloan Kettering Inst Cancer Gangliosid-klh-konjugatimpfstoffe mit qs-21 zur verzögerung des wiederauftretens eines melanoms
WO2002062810A2 (en) 2000-11-29 2002-08-15 Bracco International B.V. Linkable sialyl lewis x analogs
EP1458242A4 (en) 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
JP2003073397A (ja) 2001-08-30 2003-03-12 Wakamoto Pharmaceut Co Ltd 合成ムチン
AU2003275954A1 (en) * 2002-11-08 2004-06-07 Danmarks Fodevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates
JP4742339B2 (ja) 2005-06-14 2011-08-10 独立行政法人産業技術総合研究所 シアル酸含有３糖化合物、それを用いるサーズウイルスまたはサーズスパイク蛋白質の検出
JP5130598B2 (ja) * 2005-09-02 2013-01-30 静岡県公立大学法人 ウイルスレセプター糖鎖認識特異性の判別方法
JP2008031156A (ja) 2006-07-07 2008-02-14 National Univ Corp Shizuoka Univ 抗ウイルス剤

Also Published As

Publication number Publication date
JP2016539172A (ja) 2016-12-15
WO2015081438A1 (en) 2015-06-11
EP3957327A1 (en) 2022-02-23
ES2904533T3 (es) 2022-04-05
EP3077405A4 (en) 2017-08-09
US20160303227A1 (en) 2016-10-20
US10363305B2 (en) 2019-07-30
CN106414472A (zh) 2017-02-15
EP3077405A1 (en) 2016-10-12
EP3077405B1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
AU2015305332B2 (en) Novel glycan conjugates and use thereof
Livingston et al. Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale
AU2011265184B2 (en) Multivalent glycopeptide constructs and uses thereof
Liu et al. NKT-cell glycolipid agonist as adjuvant in synthetic vaccine
KR20170032241A (ko) 최소 사포닌 유사체, 이의 합성법 및 용도
KR20150111941A (ko) 보다 높은 탄수화물 항원 밀도 및 신규한 사포닌 애쥬번트를 갖는 백신
US20110229510A1 (en) Glycopeptide constructs and uses thereof
CA1337403C (en) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
US20030170249A1 (en) Vaccines directed to cancer-associated carbohydrate antigens
Mat Rani et al. Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers
US20240042000A1 (en) Carbohydrate structures and uses thereof
Ma et al. Enhanced Antitumor Immunity of a Globo H‐Based Vaccine Enabled by the Combination Adjuvants of 3D‐MPL and QS‐21
EP3077405B1 (en) Anti-ganglioside compound for targeting cancer and generating antibodies
HK40064500A (en) Anti-ganglioside compound for targeting cancer and generating antibodies
Manabe et al. Conjugation Strategies for Development
Manabe et al. Conjugation Strategies for Development of Bioactive Middle Molecules
Apostolopoulos et al. Carbohydrate-Based Targets and Vehicles for Cancer and Infectious Diseases Vaccines
Tong et al. A synthetic GD2 carbohydrate tetramer vaccine elicits tumor-killing antibodies and is therapeutic against GD2+ tumors
Rashidijahanabad Development of Carbohydrate Based Conjugate Vaccines Using Qβ Virus Like Particles with Anti-bacterial or Anti-cancer Properties
Apostolopoulos Carbohydrate-Based Targets and Vehicles

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191204